Keyword: Aubagio

Celgene's MS candidate ozanimod might have challenged some big blockbusters in the field, but an FDA decision means it won't happen anytime soon.

Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.

Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.

A U.S. appeals court sided with Biogen in a lawsuit claiming execs weren't open with investors about Tecfidera's sales trajectory after the death of a patient taking the drug.

Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth noting.

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.

Biogen's Tecfidera may be slowing down, but Sanofi rival Aubagio isn't. And that's a problem for the Massachusetts biotech.

The multiple sclerosis drug market shifted to oral disease-modifying therapies in 2016. One big reason? Patient requests, according to new research.

Multiple sclerosis drugmakers are in a fix: These days, the U.S. market isn’t delivering the kind of growth that had been fueling big increases in sales.